Xianghua Huang
The Second Hospital of Hebei Medical University, China
Title: Clinical validation of high risk HPV DNA testing versus cytology for predicting cervical cancer
Biography
Biography: Xianghua Huang
Abstract
Objective: Cervical cancer and its precancerous lesions are caused by persistent high risk human papilloma virus (HPV) infection. Some studies suggest that HPV test is safe, effective and sensitive than cytology. Considering the previously published literature draw that conclusion only based on taking CIN2/3 and above as the endpoint rather than that cervical carcinoma itself, this study was conducted to compare the validity of the high risk HPV test to Thinprep cytologic test for predicting cervical cancer. Design: Retrospective study Setting: Department of Obstetrics and Gynecology, The second hospital of Hebei Medical University, Shijiazhuang, China. Methods: Two hundred and forty-seven cases of histologically confirmed cervical cancer were collected from January 2004 to September 2015. Among them, ThinPrep cytological results and cobas hr-HPV DNA testing results were observed in 164 patients 1 year ago. Results: Cytological results was negative in 17.4% of 132 cases one years before the histological diagnosis. The negative rate of squamous cell carcinoma and adenocarcinoma were 15.5% and 21.1% respectively. HPV was negative in 13.3% of 120 cases. The HPV negative rate of adenocarcinoma was higher than that of squamous cell carcinoma (47.1% vs 6.1%). In 88 patients had both HPV test and cytology results, 14 (15.9%) cases were HPV negative, but only 4 (4.5%) cases were negative. Conclusion: HPV screening for identifying cervical cancer has a relatively higher negative rate than cytology test. Cytology and HPV test combination is better than HPV test alone for cervical cancer prevention and primary screening.